Sol-Gel Technologies (SLGL) Cash & Equivalents (2015 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Cash & Equivalents of $10.1 million for Q1 2026, down 39.99% year-over-year from $16.9 million in Q1 2025, and down 8.13% quarter-over-quarter from $11.0 million in Q4 2025.
Analysis
Sol-Gel Technologies (SLGL) Cash & Equivalents (2015 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Cash & Equivalents for 11 consecutive years, with $10.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 39.99% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (down 39.99% YoY), while the FY2025 annual figure was $11.0 million, down 46.61% from the prior year.
- Cash & Equivalents eased to $10.1 million in Q1 2026 per SLGL's latest filing, from $11.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $21.3 million in Q1 2022 and bottomed at $6.7 million in Q3 2025.
- Historically, Cash & Equivalents has averaged $13.6 million across 5 years, with a median of $12.7 million in 2024.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 80.39% — and 2024, when it soared 159.4%.
- Sol-Gel Technologies' Cash & Equivalents stood at $12.4 million in 2022, then sank by 39.64% to $7.5 million in 2023, then soared by 159.4% to $19.5 million in 2024, then sank by 43.39% to $11.0 million in 2025, then slipped by 8.13% to $10.1 million in 2026.
- Business Quant data shows SLGL's Cash & Equivalents at $10.1 million in Q1 2026, $11.0 million in Q4 2025, and $6.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | 16.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.66 Mn |
| Mar 31, 2026 | 10.14 Mn |
| Dec 31, 2025 | 11.03 Mn |
| Sep 30, 2025 | 6.71 Mn |
| Jun 30, 2025 | 20.67 Mn |
| Mar 31, 2025 | 16.89 Mn |
| Dec 31, 2024 | 19.49 Mn |
| Sep 30, 2024 | 13.42 Mn |
| Jun 30, 2024 | 12.71 Mn |
| Mar 31, 2024 | 11.21 Mn |
| Dec 31, 2023 | 7.51 Mn |
| Sep 30, 2023 | 14.14 Mn |
| Jun 30, 2023 | 16.79 Mn |
| Mar 31, 2023 | 6.81 Mn |
| Dec 31, 2022 | 12.45 Mn |
| Sep 30, 2022 | 8.50 Mn |
| Jun 30, 2022 | 21.24 Mn |
| Mar 31, 2022 | 21.25 Mn |
| Dec 31, 2021 | 20.09 Mn |
| Sep 30, 2021 | 43.35 Mn |